메뉴 건너뛰기




Volumn 43, Issue 5, 2013, Pages 568-577

Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis

Author keywords

5 grass pollen tablet; Allergen; Allergic rhinoconjunctivitis; Discontinuous regimen; Grass pollen; Post treatment efficacy; Pre and co seasonal treatment; Rhinoconjunctivitis; Sublingual immunotherapy

Indexed keywords

300 IR 5; ANTIALLERGIC AGENT; UNCLASSIFIED DRUG;

EID: 84876702869     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12100     Document Type: Article
Times cited : (84)

References (24)
  • 1
    • 47749085883 scopus 로고    scopus 로고
    • The diagnosis and management of rhinitis: an updated practice parameter
    • Wallace DV, Dykewicz MS, Bernstein DI et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122:S1-84.
    • (2008) J Allergy Clin Immunol , vol.122
    • Wallace, D.V.1    Dykewicz, M.S.2    Bernstein, D.I.3
  • 3
    • 33847607537 scopus 로고    scopus 로고
    • The burden of allergic rhinitis
    • Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007; 28:3-9.
    • (2007) Allergy Asthma Proc , vol.28 , pp. 3-9
    • Nathan, R.A.1
  • 4
    • 78650918994 scopus 로고    scopus 로고
    • Allergen immunotherapy: a practice parameter third update
    • Cox L, Nelson H, Lockey R et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1-55.
    • (2011) J Allergy Clin Immunol , vol.127
    • Cox, L.1    Nelson, H.2    Lockey, R.3
  • 5
    • 80051734103 scopus 로고    scopus 로고
    • Mechanisms of immunotherapy to aeroallergens
    • Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy 2011; 41:1235-46.
    • (2011) Clin Exp Allergy , vol.41 , pp. 1235-1246
    • Shamji, M.H.1    Durham, S.R.2
  • 6
    • 78650898599 scopus 로고    scopus 로고
    • Disease-modifying effect and economic implications of sublingual immunotherapy
    • Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. J Allergy Clin Immunol 2011; 127:44-5.
    • (2011) J Allergy Clin Immunol , vol.127 , pp. 44-45
    • Canonica, G.W.1    Passalacqua, G.2
  • 7
    • 80255141811 scopus 로고    scopus 로고
    • Long-term clinical and immunological effects of allergen immunotherapy
    • Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11:586-93.
    • (2011) Curr Opin Allergy Clin Immunol , vol.11 , pp. 586-593
    • Eifan, A.O.1    Shamji, M.H.2    Durham, S.R.3
  • 8
    • 75849127328 scopus 로고    scopus 로고
    • Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009
    • Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64(Suppl 91):1-59.
    • (2009) Allergy , vol.64 , Issue.SUPPL. 91 , pp. 1-59
    • Canonica, G.W.1    Bousquet, J.2    Casale, T.3
  • 9
    • 36248986032 scopus 로고    scopus 로고
    • Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis
    • Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-45.
    • (2007) J Allergy Clin Immunol , vol.120 , pp. 1338-1345
    • Didier, A.1    Malling, H.J.2    Worm, M.3
  • 10
    • 58149109018 scopus 로고    scopus 로고
    • Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis
    • Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123(160-66):e3.
    • (2009) J Allergy Clin Immunol , vol.123 , Issue.160-166
    • Wahn, U.1    Tabar, A.2    Kuna, P.3
  • 11
    • 80052259321 scopus 로고    scopus 로고
    • Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis
    • Didier A, Worm M, Horak F et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128:559-66.
    • (2011) J Allergy Clin Immunol , vol.128 , pp. 559-566
    • Didier, A.1    Worm, M.2    Horak, F.3
  • 12
    • 79955375673 scopus 로고    scopus 로고
    • The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials
    • Grouin JM, Vicaut E, Jean-Alphonse S et al. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy 2011; 41:1282-8.
    • (2011) Clin Exp Allergy , vol.41 , pp. 1282-1288
    • Grouin, J.M.1    Vicaut, E.2    Jean-Alphonse, S.3
  • 13
    • 0032845559 scopus 로고    scopus 로고
    • Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire
    • Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999; 104:364-9.
    • (1999) J Allergy Clin Immunol , vol.104 , pp. 364-369
    • Juniper, E.F.1    Thompson, A.K.2    Ferrie, P.J.3    Roberts, J.N.4
  • 14
    • 84876708386 scopus 로고    scopus 로고
    • Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London: European Medicines Agency
    • Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London: European Medicines Agency, 2008.
    • (2008)
  • 15
    • 84870294264 scopus 로고    scopus 로고
    • Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE
    • e1
    • Cox LS, Casale TB, Nayak AS et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012; 130:1327-34. e1.
    • (2012) J Allergy Clin Immunol , vol.130 , pp. 1327-1334
    • Cox, L.S.1    Casale, T.B.2    Nayak, A.S.3
  • 16
    • 84887023687 scopus 로고    scopus 로고
    • Efficacy and safety of 2-month pre-seasonal and co-seasonal treatment with a 5-grass pollen allergen extract sublingual tablet
    • Zeldin RK, Rodriguez P, Abiteboul K, Montagut A, de Blay F. Efficacy and safety of 2-month pre-seasonal and co-seasonal treatment with a 5-grass pollen allergen extract sublingual tablet. Allergy Asthma Proc 2013.
    • (2013) Allergy Asthma Proc
    • Zeldin, R.K.1    Rodriguez, P.2    Abiteboul, K.3    Montagut, A.4    de Blay, F.5
  • 17
    • 0033549827 scopus 로고    scopus 로고
    • Long-term clinical efficacy of grass-pollen immunotherapy
    • Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
    • (1999) N Engl J Med , vol.341 , pp. 468-475
    • Durham, S.R.1    Walker, S.M.2    Varga, E.M.3
  • 18
    • 33644900473 scopus 로고    scopus 로고
    • Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood
    • Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61:198-201.
    • (2006) Allergy , vol.61 , pp. 198-201
    • Eng, P.A.1    Borer-Reinhold, M.2    Heijnen, I.A.3    Gnehm, H.P.4
  • 19
    • 0036217348 scopus 로고    scopus 로고
    • Long-term efficacy of preseasonal grass pollen immunotherapy in children
    • Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57:306-12.
    • (2002) Allergy , vol.57 , pp. 306-312
    • Eng, P.A.1    Reinhold, M.2    Gnehm, H.P.3
  • 20
    • 34447132918 scopus 로고    scopus 로고
    • Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study
    • Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-8.
    • (2007) Allergy , vol.62 , pp. 943-948
    • Jacobsen, L.1    Niggemann, B.2    Dreborg, S.3
  • 21
    • 39149127957 scopus 로고    scopus 로고
    • Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years
    • e2.
    • Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-18, e2.
    • (2008) J Allergy Clin Immunol , vol.121 , pp. 512-518
    • Dahl, R.1    Kapp, A.2    Colombo, G.3
  • 22
    • 33746691245 scopus 로고    scopus 로고
    • Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis
    • Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-40.
    • (2006) J Allergy Clin Immunol , vol.118 , pp. 434-440
    • Dahl, R.1    Kapp, A.2    Colombo, G.3
  • 23
    • 73149111527 scopus 로고    scopus 로고
    • Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet
    • Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-8.
    • (2010) J Allergy Clin Immunol , vol.125 , pp. 131-138
    • Durham, S.R.1    Emminger, W.2    Kapp, A.3
  • 24
    • 84857797855 scopus 로고    scopus 로고
    • SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial
    • Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-25.
    • (2012) J Allergy Clin Immunol , vol.129 , pp. 717-725
    • Durham, S.R.1    Emminger, W.2    Kapp, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.